Non-steroidal anti-inflammatory drugs: indications for use.
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely used of all therapeutic agents. Although they are effective analgesics they do have significant adverse side-effects. Before treatment is started the prescriber should always weigh efficacy against possible side-effects. NSAIDs vary in their selectivity for inhibiting the two types of cyclo-oxygenase. An NSAID should therefore be chosen on the basis of the incidence of associated side-effects.
Middleton
Carolyn
C
Nevill Hall Hospital, Gwent Healthcare NHS Trust.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D001791:Blood Platelet Disorders / Q000139:chemically induced; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D015232:Dinoprostone / Q000276:immunology; D011464:Epoprostenol / Q000276:immunology; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced; D006801:Humans; D018836:Inflammation Mediators / Q000276:immunology; D007527:Isoenzymes / Q000187:drug effects / Q000276:immunology; D007674:Kidney Diseases / Q000139:chemically induced; D008565:Membrane Proteins; D018579:Patient Selection; D011451:Prostaglandin-Endoperoxide Synthases / Q000187:drug effects / Q000276:immunology; D012307:Risk Factors; D013928:Thromboxane A2 / Q000276:immunology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D018836:Inflammation Mediators; D007527:Isoenzymes; D008565:Membrane Proteins; D013928:Thromboxane A2; D011464:Epoprostenol; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; C496511:PTGS1 protein, human; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D015232:Dinoprostone